FilingFirehose · free AI preview
GYRE THERAPEUTICS, INC.
GYRE · AI-generated SEC analysis preview · refreshes when data changes
⚠️ Red flag 8-Ks: 1
Types: Officer Departure
Gyre Therapeutics (GYRE) filed an 8-K on May 4, 2026 disclosing an officer departure, along with related items spanning compensation, financial statements, and regulatory filings. While a single departure event doesn't necessarily signal distress, the timing and scope of reported items warrant context. The full $49 Report pulls 12 months of SEC filings to calculate dilution risk scores, frames this departure within the company's financing and equity history, and scans for AI-detected anomalies in disclosure patterns. The full $49 Report adds institutional ownership trends, cash runway analysis, and a quantified risk profile across governance, capital structure, and operational stability.
Want the full 5-section $49 Report on GYRE?
Dilution risk score · 12 months of 8-K context · financing history · AI risk signals · bottom-line framing. Delivered in ~5 minutes.
See a real sample report →
This preview was AI-generated from FilingFirehose's SEC EDGAR ingestion pipeline.
Not investment advice. Verify all claims against original filings.